Fenwick & West and Paul Hastings advised ACELYRIN, INC. on the transaction, and Cooley advised Alumis Inc. ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company...
ACELYRIN’s Merger with Alumis
ACELYRIN’s $621 Million Initial Public Offering
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
ACELYRIN’s $300 Million Series C Financing Round
Goodwin Procter advised ACELYRIN on the deal. ACELYRIN announced the completion of its $300 million Series C financing round which was led by Access Biotechnology with participation...